It is true that for these initial protocols, they are only testing becoming symptomatic versus prevention of transmission. That said, all the trials (at least in phase 1/2) are also looking at antibody levels[1][2], which would indicate less likelihood of transmission.
Remember, all these vaccines aren't yet applying for full approval, but an EUA (Emergency Use Authorization). I fully expect that the FDA would want to see data on transmission before full approval; but that is harder to acquire, so it makes sense they wouldn't wait for that specific data.
As someone in the AZD12222 (AstraZeneca/Oxford) trial, I can confirm that they are following all participants for a full 2 years. In this time (versus the ~3 months each Phase 3
trial has run for), there will be much more time to see if these vaccines prevent transmission, not just prevent symptoms.
With all that said, many thousands of live will be saved by getting these vaccines out now, even if they are only partially effective. After all, someone who can't get sick can return to a more normal life, since they won't have issues if they were to get SARS-COV-2 infection later on.
[1] https://biology.mit.edu/undergraduate/current-students/subje... [Lecture 10, with a NIH researcher who worked on the Moderna vaccine]
[2] https://www.thelancet.com/journals/lancet/article/PIIS0140-6... [Phase 2/3 study of AstraZeneca vaccine, figure shows neutralizing antibody levels]